Mike Nally, Generate:Biomedicines CEO
Flagship’s AI unicorn Generate raises $273M Series C, as first drug in 17-program pipeline enters the clinic
Flagship Pioneering’s AI-focused startup Generate:Biomedicines has raised another megaround that will push multiple drug programs into the clinic.
The Somerville, MA-based biotech said Thursday it …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
